Affiliation:
1. Renal Division Peking University First Hospital Peking University Institute of Nephrology Key Laboratory of Renal Disease Ministry of Health of China Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University) Ministry of Education Beijing 100034 China
2. Beijing National Laboratory for Molecular Sciences CAS Laboratory of Colloid and Interface and Thermodynamics CAS Research/Education Center for Excellence in Molecular Sciences Center for Carbon Neutral Chemistry Institute of Chemistry Chinese Academy of Sciences Beijing 100190 China
3. Department of Cardiology Institute of Vascular Medicine NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides State Key Laboratory of Vascular Homeostasis and Remodeling Peking University Beijing Key Laboratory of Cardiovascular Receptors Research Peking University Third Hospital Beijing 100191 China
Abstract
AbstractNanotechnology profoundly affects the advancement of medicine. Limitations in diagnosing and treating cancer and chronic diseases promote the growth of nanomedicine. However, there are very few analytical and descriptive studies regarding the trajectory of nanomedicine, key research powers, present research landscape, focal investigative points, and future outlooks. Herein, articles and reviews published in the Science Citation Index Expanded of Web of Science Core Collection from first January 2000 to 18th July 2023 are analyzed. Herein, a bibliometric visualization of publication trends, countries/regions, institutions, journals, research categories, themes, references, and keywords is produced and elaborated. Nanomedicine‐related academic output is increasing since the COVID‐19 pandemic, solidifying the uneven global distribution of research performance. While China leads in terms of publication quantity and has numerous highly productive institutions, the USA has advantages in academic impact, commercialization, and industrial value. Nanomedicine integrates with other disciplines, establishing interdisciplinary platforms, in which drug delivery and nanoparticles remain focal points. Current research focuses on integrating nanomedicine and cell ferroptosis induction in cancer immunotherapy. The keyword “burst testing” identifies promising research directions, including immunogenic cell death, chemodynamic therapy, tumor microenvironment, immunotherapy, and extracellular vesicles. The prospects, major challenges, and barriers to addressing these directions are discussed.
Funder
National Natural Science Foundation of China
Beijing Nova Program
Natural Science Foundation of Beijing Municipality
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献